325 related articles for article (PubMed ID: 19240944)
1. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.
Cuevas C; Francesch A
Nat Prod Rep; 2009 Mar; 26(3):322-37. PubMed ID: 19240944
[TBL] [Abstract][Full Text] [Related]
2. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.
Schöffski P; Wolter P; Clement P; Sciot R; De Wever I; Wozniak A; Stefan C; Dumez H
Future Oncol; 2007 Aug; 3(4):381-92. PubMed ID: 17661712
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and cytotoxic evaluation of some cribrostatin-ecteinascidin analogues.
Wright BJ; Chan C; Danishefsky SJ
J Nat Prod; 2008 Mar; 71(3):409-14. PubMed ID: 18278868
[TBL] [Abstract][Full Text] [Related]
5. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
Carter NJ; Keam SJ
Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287
[TBL] [Abstract][Full Text] [Related]
6. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
Gennigens C; Jerusalem G
Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
[TBL] [Abstract][Full Text] [Related]
7. Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics.
Le VH; Inai M; Williams RM; Kan T
Nat Prod Rep; 2015 Feb; 32(2):328-47. PubMed ID: 25273374
[TBL] [Abstract][Full Text] [Related]
8. Trabectedin in soft tissue sarcomas.
Brodowicz T
Future Oncol; 2014 Jun; 10(8 Suppl):s1-5. PubMed ID: 25048043
[TBL] [Abstract][Full Text] [Related]
9. Preclinical and clinical results with the natural marine product ET-743.
D'Incalci M; Jimeno J
Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
[TBL] [Abstract][Full Text] [Related]
10. Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.
Vincenzi B; Napolitano A; Frezza AM; Schiavon G; Santini D; Tonini G
Pharmacogenomics; 2010 Jun; 11(6):865-78. PubMed ID: 20504257
[TBL] [Abstract][Full Text] [Related]
11. Synthetic studies on ecteinascidin-743: constructing a versatile pentacyclic intermediate for the synthesis of ecteinascidins and saframycins.
Jin W; Metobo S; Williams RM
Org Lett; 2003 Jun; 5(12):2095-8. PubMed ID: 12790537
[TBL] [Abstract][Full Text] [Related]
12. Unique features of trabectedin mechanism of action.
Larsen AK; Galmarini CM; D'Incalci M
Cancer Chemother Pharmacol; 2016 Apr; 77(4):663-71. PubMed ID: 26666647
[TBL] [Abstract][Full Text] [Related]
13. New drugs from the sea.
D'Incalci M; Simone M; Tavecchio M; Damia G; Garbi A; Erba E
J Chemother; 2004 Nov; 16 Suppl 4():86-9. PubMed ID: 15688619
[TBL] [Abstract][Full Text] [Related]
14. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production.
Allavena P; Signorelli M; Chieppa M; Erba E; Bianchi G; Marchesi F; Olimpio CO; Bonardi C; Garbi A; Lissoni A; de Braud F; Jimeno J; D'Incalci M
Cancer Res; 2005 Apr; 65(7):2964-71. PubMed ID: 15805300
[TBL] [Abstract][Full Text] [Related]
16. Stereospecific formal total synthesis of ecteinascidin 743.
Zheng S; Chan C; Furuuchi T; Wright BJ; Zhou B; Guo J; Danishefsky SJ
Angew Chem Int Ed Engl; 2006 Mar; 45(11):1754-9. PubMed ID: 16496274
[No Abstract] [Full Text] [Related]
17. The potent anticancer compound ecteinascidin-743 (ET-743) as its 2-propanol disolvate.
Sainz-Diaz CI; Manzanares I; Francesch A; Garcia-Ruiz J
Acta Crystallogr C; 2003 Apr; 59(Pt 4):O197-8. PubMed ID: 12682407
[TBL] [Abstract][Full Text] [Related]
18. Enhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells.
Acikgoz E; Guven U; Duzagac F; Uslu R; Kara M; Soner BC; Oktem G
PLoS One; 2015; 10(10):e0141090. PubMed ID: 26485709
[TBL] [Abstract][Full Text] [Related]
19. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.
Monk BJ; Dalton H; Benjamin I; Tanović A
Curr Pharm Des; 2012; 18(25):3754-69. PubMed ID: 22591421
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenic effects of trabectedin (Yondelis; ET-743) on human breast cancer cells.
Atmaca H; Uzunoglu S
Eur Cytokine Netw; 2014 Mar; 25(1):1-7. PubMed ID: 24941346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]